$4.89
5.96% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US68621F1021
Symbol
ORGO

Organogenesis Holdings Stock price

$4.89
+0.40 8.91% 1M
+1.23 33.61% 6M
+1.69 52.81% YTD
+2.47 102.07% 1Y
+0.17 3.60% 3Y
+0.82 20.15% 5Y
-4.86 49.85% 10Y
-4.86 49.85% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.28 5.96%
ISIN
US68621F1021
Symbol
ORGO
Industry

Key metrics

Basic
Market capitalization
$585.5m
Enterprise Value
$477.1m
Net debt
positive
Cash
$110.0m
Shares outstanding
126.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.3 | 1.2
EV/Sales
1.0 | 1.0
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
77.4%
Return on Equity
-0.2%
ROCE
1.3%
ROIC
1.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$458.8m | $498.9m
EBITDA
$22.5m | $52.6m
EBIT
$5.2m | $11.7m
Net Income
$-20.4m | $-3.9m
Free Cash Flow
$-7.0m
Growth (TTM | estimate)
Revenue
5.4% | 3.5%
EBITDA
-19.8% | 36.6%
EBIT
-59.1% | -45.7%
Net Income
-450.4% | -312.8%
Free Cash Flow
-202.8%
Margin (TTM | estimate)
Gross
75.9%
EBITDA
4.9% | 10.6%
EBIT
1.1%
Net
-4.5% | -0.8%
Free Cash Flow
-1.5%
More
EPS
$-0.2
FCF per Share
$-0.1
Short interest
22.3%
Employees
869
Rev per Employee
$550.0k
Show more

Is Organogenesis Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Organogenesis Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Organogenesis Holdings forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Organogenesis Holdings forecast:

Buy
89%
Hold
11%

Financial data from Organogenesis Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
459 459
5% 5%
100%
- Direct Costs 111 111
2% 2%
24%
348 348
6% 6%
76%
- Selling and Administrative Expenses 295 295
10% 10%
64%
- Research and Development Expense 48 48
5% 5%
10%
23 23
20% 20%
5%
- Depreciation and Amortization 17 17
12% 12%
4%
EBIT (Operating Income) EBIT 5.19 5.19
59% 59%
1%
Net Profit -20 -20
450% 450%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Organogenesis Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organogenesis Holdings Stock News

Neutral
Seeking Alpha
4 days ago
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants David C. Francisco - Chief Financial Officer Gary S.
Neutral
The Motley Fool
5 days ago
ORGO Sales Drop 23%
Neutral
GlobeNewsWire
5 days ago
CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025.
More Organogenesis Holdings News

Company Profile

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Head office United States
CEO Gary Gillheeney
Employees 869
Founded 1985
Website investors.organogenesis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today